Products and Resources Catalog

Please join us for the first webinar in the Opioid Prescribers' Series. This webinar will describe how to improve patient safety by instituting a set of universal precautions for opioid prescribing in primary care based on leading clinical guidelines. Key points to be addressed are: 1) How the propose guideline principles were determined, 2) Key guideline principles for opioid prescribing, and 3) Methods for guideline implementation.

This presentation provides an overview of drug and alcohol use in South Africa, with a particular focus on people living with HIV. Additionally, the South Africa HIV ATTC's mission, objectives, and training targets are contextualised within this drug and alcohol addiction context.

Dr. Ryan Westergaard specializes in infectious disease and substance use disorder treatment. In this webinar, he provides an overview of the intersection between injection drug use, opioid use disorders, and HIV and viral hepatitis infections.

FAQ Sheet captures questions and answer session of webinar presented by Dr. Dennis McCarty, April 3, 2018, "Treatment and Prevention of Opioid Use Disorder: Overview."

This presentation was created and delivered by Mr. Kgalabi Ngako, a National Department of Health representative for the Mental Health and Substance Abuse Directorate. It discusses adopting Screening, Brief Intervention and Referral to Treatment (SBIRT) curriculum as a strategy to combat substance use disorders.

Featuring opioids and technology, Jean Bennett, Ph.D., SAMHSA Regional Administrator (Region 3), Central East on the Move, new resources, Region 3 news, Monthly Health Check, and affirmations.

Monthly electronic newsletter featuring Great Lakes ATTC training events and other topics.

Mid-America ATTC has developed a 2018 version of the Hepatitis Awareness Month (May) Info Sheet and Bulletin Insert. Side one has been updated to focus on the dual epidemics of the opioid crisis and hepatitis C virus (HCV). Although the document was initially designed for the faith community, it is appropriate as an educational flyer for much broader audiences. This product can be easily downloaded and used by churches, temples and mosques for their Sunday/Sabbath-day bulletins, newsletter

Joseph O. Merrill, MD, MPH, UW Associate Professor of Medicine April 25, 2018 Dr. Merrill is a UW associate professor of medicine and a certified expert in addiction medicine. He has clinical and research expertise in primary care, addiction medicine, pain medicine, and HIV medicine. As a member of the UW School of Medicine Colleges Faculty, he is active in medical student education. He teaches students, residents, and practicing physicians in a wide variety of settings. Download slides | Watch recording

Naloxone temporarily reverses the effects of opioid overdose:slowed or stopped breathing and is typically utilized by first responders. The US surgeon general issued an advisory Thursday, April 5, 2018 recommending that more Americans carry the opioid overdose-reversing drug, naloxone which is sold under the brand name Narcan.

Dr. Dennis McCarty, PhD, provides an overview of treatment and prevention of opioid use disorder, with a discussion of effective use of medications.

This webinar, presented by K. Michelle Peavy, PhD, Research and Training Manager, Evergreen Treatment Services (ETS), examined the concept of patient-centered care in an OTP setting. Dr. Peavy, Research and Training Manager at Evergreen Treatment Services (ETS), will describe a treatment model that leverages patient-centered care components and enhances retention among individuals who struggle with ongoing drug use, and discuss clinical implications of that model. Download slides | Watch recording Webinar category: Opioids, Medication Treatment

This is a one-page flyer detailing the objectives, mission and contact information of the South Africa HIV ATTC.

The Short-term Opioid Withdawal Using Buprenorphine (Bup Detox) Blending Team designed a training package to instruct treatment providers on the administration of aBup Detox Brochure Cover unique,13-day Buprenorphine taper intervention for opioid dependent patients. Research conducted in both inpatient and outpatient settings by the NIDA Clinical Trials Network demonstrated that, in contrast with the clonidine treatment group, patients receiving Buprenorphine provided more opioid-negative urine samples upon completion of the intervention. This training assumes some basic prior information about what Buprenorphine is and how it is used.            

This multidisciplinary six-module training series provides information about the use of medication-assisted treatment for opioid use disorders.

This skills building workshop introduced CBT for adolescent substance use. Presented by Sara Becker, PhD.

This training presentation provides information about the use of Buprenorphine in medication-assisted treatment for opioid use disorders.

This training presentation address Medication Assisted Treatment for Pregnant or Parenting Women Offenders with a Substance Use Disorder.